Quantisnow Logo
Dashboard

Avantor® Opens New Bridgewater Innovation Center Focused on Solving Life Science's Biggest Challenges

$AVTR
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $AVTR alert in real time by email

RADNOR, Pa., Nov. 14, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the opening of its new flagship Bridgewater Innovation Center. The state-of-the-art research and development facility, located in Bridgewater, NJ, is part of Avantor's network of 13 research and innovation centers across the globe.

Avantor's new Bridgewater Innovation Center spans 60,000 square feet, doubling its previous laboratory and pilot plant capacity. Purpose-designed for collaborative work, the center houses spaces for upstream and downstream process development, dedicated analytical testing labs, and a viral vector laboratory. An expanded pilot plant supports scale-up simulations, enabling rapid customization across the entire bioprocessing workflow.

"Our new Bridgewater Innovation Center is twice the size of our previous facility and adds capacity, talent and capabilities to support the growing demands for monoclonal antibodies, cell and gene therapy and mRNA workflows," said Michael Stubblefield, President and CEO of Avantor. "Working side-by-side with customers in our network of innovation centers across the globe enables us to power science at every step to deliver life-changing therapies faster, and more cost effectively."

The Bridgewater Innovation Center allows Avantor to optimize and accelerate biomanufacturing processes at scale; resulting in faster problem solving, streamlined knowledge exchange, and strategic co-innovation. Staffed with Ph.D. scientists, bioengineers, biologists, and process engineers, this center enhances both capacity and expertise to support customers' needs. The facility also supports Avantor's sustainability goals, reinforcing the Company's commitment to environmental responsibility.

For more information about the Bridgewater Innovation Center, visit: https://www.avantorsciences.com/us/en/about/innovation-in-biopharma/avantor-bridgewater-innovation-center. 

About Avantor

Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

Global Media Contact

Eric Van Zanten

Head of External Communications

Avantor

610-529-6219

Eric.VanZanten@avantorsciences.com

Investor Relations Contact

Christina Jones

Vice President, Investor Relations

Avantor

805-617-5297

Christina.Jones@avantorsciences.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-opens-new-bridgewater-innovation-center-focused-on-solving-life-sciences-biggest-challenges-302304526.html

SOURCE Avantor and Financial News

Get the next $AVTR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVTR

DatePrice TargetRatingAnalyst
1/17/2025$29.00 → $25.00Buy → Neutral
UBS
8/28/2024$30.00Overweight
Wells Fargo
7/10/2024$30.00 → $23.00Buy → Neutral
Citigroup
1/4/2024$19.50 → $26.00In-line → Outperform
Evercore ISI
12/11/2023$21.00 → $28.00Market Perform → Outperform
TD Cowen
9/28/2023$22.00Mkt Perform
Bernstein
7/31/2023$22.00 → $21.00Outperform → In-line
Evercore ISI
7/31/2023Outperform → Mkt Perform
William Blair
More analyst ratings

$AVTR
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Avantor® Provides First Look at Recently Completed Hydration Expansion at DCAT Week 2025

    Facility in Gliwice, Poland to boost biopharma manufacturers' efficiency and speed to market of therapies RADNOR, Pa., March 17, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services in the life sciences and advanced technology industries, announces that Ger Brophy, PhD, head of Avantor's Scientific Advisory Board, will present highlights of the recently completed expansion at its flagship European manufacturing site at Drug, Chemical & Associated Technologies Association (DCAT) Week 2025. Dr. Brophy's presentation will take place as part of the Member Company Announcement Forum on Monday, March 17, at approximately 9:15 am easter

    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Avantor® to Present at TD Cowen's 45th Annual Health Care Conference

    RADNOR, Pa., Feb. 19, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that President and CEO, Michael Stubblefield, will present at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, at 11:50 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days

    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Silq Technologies Corp. and NuSil Technology LLC Announce Collaboration Agreement to Drive Broad-based Adoption of Silq's Novel Surface Treatment Technology

    Silq Technologies Corporation, a privately held advanced materials science company, and NuSil Technology LLC, a subsidiary of Avantor Inc., Radnor, Pa. (NYSE:AVTR), and a leading global supplier of high-quality silicones for long-term medical implants, have entered into an agreement to facilitate the utilization of Silq's zwitterionic surface treatment technology on medical devices manufactured with NuSil silicone products. Zwitterion surface technology has been a major subject of research in academia for several decades because of its potential to reduce medical implant-associated infections and complications without the use of antibiotics. Zwitterion functionalized surfaces have also bee

    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$AVTR
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AVTR
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AVTR
 SEC Filings

See more

$AVTR
 Leadership Updates

Live Leadership Updates

See more

  • Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

    RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    $AVTR
    $GRAL
    $NXPI
    $STT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

  • Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600

    NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS

    $APO
    $AVTR
    $HIBB
    $QDEL
    Investment Managers
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$AVTR
 Financials

Live finance-specific insights

See more

  • Avantor® Reports Fourth Quarter and Full Year 2024 Results

    Fourth Quarter 2024 Net sales of $1.69 billion, decrease of 2%; organic growth of 1%Net income of $500.4 million; Adjusted EBITDA of $307.7 millionDiluted GAAP EPS of $0.73; adjusted EPS of $0.27Operating cash flow of $173.3 million; free cash flow of $222.1 millionFull Year 2024 Net sales of $6.78 billion, decrease of 3%; organic decline of 2%Net income of $711.5 million; Adjusted EBITDA of $1,198.8 millionDiluted GAAP EPS of $1.04; adjusted EPS of $0.99Operating cash flow of $840.8 million; free cash flow of $768.3 millionRADNOR, Pa., Feb. 7, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences

    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Avantor® to Report Fourth Quarter and Full Year 2024 Earnings on Friday, February 7, 2025

    RADNOR, Pa., Jan. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 7, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscie

    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Avantor® Reports Third Quarter 2024 Results

    Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7%Net income of $57.8 million; Adjusted EBITDA of $302.5 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.26Operating cash flow of $244.8 million; free cash flow of $204.0 millionRADNOR, Pa., Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2024. "Our team delivered another quarter o

    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$AVTR
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more